Kathryn L. Parsons

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

Pharmacy, Oncology, Pharmacology +17

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al. · Cancer Cell · 2009 · 831 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons et al. · Breast Cancer Research and Treatment · 2010 · 533 citations

Medicine, Oncology, Pharmacology +11

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Jagath R. Junutula, Kelly M. Flagella, Richard Graham et al. · Clinical Cancer Research · 2010 · 292 citations

Pharmacy, Medicinal Chemistry, Oncology +17

Superior <i>In vivo</i> Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

Teemu T. Junttila, Kathryn L. Parsons, Christine Olsson et al. · Cancer Research · 2010 · 216 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17